Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody

K Ohnuma; Bart Haagmans; R Hatano; Stalinraj Victor; H Mou; S Iwata; NH Dang; BJ (Berend Jan) Bosch; C Morimoto

doi:10.1128/JVI.02448-13

Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody

K Ohnuma, Bart Haagmans, R Hatano, Stalinraj Victor, H Mou, S Iwata, NH Dang, BJ (Berend Jan) Bosch, C Morimoto

Research output: Contribution to journal › Article › Academic › peer-review

85 Citations (Scopus)

Abstract

We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

Original language	Undefined/Unknown
Pages (from-to)	13892-13899
Number of pages	8
Journal	Journal of Virology
Volume	87
Issue number	24
DOIs	https://doi.org/10.1128/JVI.02448-13
Publication status	Published - 2013

Research programs

EMC MM-04-27-01

Access to Document

10.1128/JVI.02448-13

http://hdl.handle.net/1765/70239

Cite this

@article{2975a68ba8e245ac8a6d5024af5f68ff,

title = "Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody",

abstract = "We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.",

author = "K Ohnuma and Bart Haagmans and R Hatano and Stalinraj Victor and H Mou and S Iwata and NH Dang and Bosch, {BJ (Berend Jan)} and C Morimoto",

year = "2013",

doi = "10.1128/JVI.02448-13",

language = "Undefined/Unknown",

volume = "87",

pages = "13892--13899",

journal = "Journal of Virology",

issn = "0022-538X",

publisher = "American Society for Microbiology",

number = "24",

}

TY - JOUR

T1 - Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody

AU - Ohnuma, K

AU - Haagmans, Bart

AU - Hatano, R

AU - Victor, Stalinraj

AU - Mou, H

AU - Iwata, S

AU - Dang, NH

AU - Bosch, BJ (Berend Jan)

AU - Morimoto, C

PY - 2013

Y1 - 2013

N2 - We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

AB - We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

U2 - 10.1128/JVI.02448-13

DO - 10.1128/JVI.02448-13

M3 - Article

C2 - 24067970

SN - 0022-538X

VL - 87

SP - 13892

EP - 13899

JO - Journal of Virology

JF - Journal of Virology

IS - 24

ER -